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Summary
The implication of complement in multiple diseases over the last 20 years
has fuelled interest in developing anti-complement drugs. To date, the
focus has been on C5; blocking cleavage of C5 prevents formation of two
pro-inflammatory activities, C5a anaphylatoxin and membrane attack
complex. The concept of C5 blockade to inhibit inflammation dates back
30 years to the description of BB5.1, an anti-C5 blocking monoclonal
antibody raised in C5-deficient mice. This antibody proved an invaluable
tool to demonstrate complement involvement in mouse disease models
and catalysed enthusiasm for anti-complement drug development, culmi-
nating in the anti-human C5 monoclonal antibody eculizumab, the most
successful anti-complement drug to date, already in clinical use for several
rare diseases. Despite its key role in providing proof-of-concept for C5
blockade, the mechanism of BB5.1 inhibition remains poorly understood.
Here, we characterized BB5.1 cross-species inhibition, C5 binding affinity
and chain specificity. BB5.1 efficiently inhibited C5 in mouse serum but
not in human or other rodent sera; it prevented C5 cleavage and C5a gen-
eration. BB5.1 bound the C5 a-chain with high affinity and slow off-rate.
BB5.1 complementarity-determining regions were obtained and docking
algorithms were used to predict the likely binding interface on mouse C5.
Keywords: complement; complement therapeutics; eculizumab; mono-
clonal antibody; mouse C5; mouse models.
Introduction
Complement is a key component of the immune system,
evolved to protect from bacterial infections; however, dys-
regulation of complement drives inflammation and leads
to pathology in many diseases.1,2 Activation of comple-
ment by way of classical, lectin or alternative pathways
triggers enzymatic cascade reactions that all result in for-
mation of C3-cleaving enzymes (convertases) and subse-
quently C5 convertases; these cleave C5 into C5a, a
potent anaphylatoxin, and C5b, which nucleates forma-
tion of membrane attack complex (MAC) by sequen-
tially binding C6 and C7. The C5b67 complex binds
membranes and sequentially recruits C8 and C9 to com-
plete the MAC.2,3 Among the array of complement pro-
teins, regulators and receptors, C5 plays a major role in
complement-mediated inflammation and for that reason
has been the favoured target for the development of anti-
complement drugs. Since the anti-C5 monoclonal anti-
body (mAb) eculizumab entered the clinic 12 years ago,
the field has grown to the point where a recent com-
pendium listed 28 anti-complement drugs in develop-
ment; of these, 12 target C5.2
The first disease targets for anti-complement drugs
were rare complement-driven diseases caused by
complement gene mutations or polymorphisms, notably
Abbreviations: Abs, absorbance; AP, alternative pathway; BSA, bovine serum albumin; C5, complement component 5; CP, classi-
cal pathway; ELISA, enzyme-linked immunosorbent assay; HBS, HEPES-buffered saline; mAb, monoclonal antibody; MAC,
membrane attack complex; PBS, phosphate-buffered saline; RbE, rabbit erythrocytes; RT, room temperature; ShEA, antibody-
sensitized sheep erythrocytes; WB, Western blot
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paroxysmal nocturnal haemoglobinuria and atypical hae-
molytic uraemic syndrome,4–7 but complement is also
implicated in many more common diseases, including
age-related macular degeneration, myasthenia gravis, and
in multiple central nervous system diseases including Alz-
heimer’s disease, neuromyelitis optica and multiple scle-
rosis.1,8 In haemolytic uraemic syndrome and paroxysmal
nocturnal haemoglobinuria, blocking MAC assembly with
the anti-C5 mAb eculizumab prevents pathology and
transforms patient outcomes.4–7
The evidence underpinning the rapid developments in
complement therapeutics has come from animal studies;
a large proportion of these studies have used the same
key agent, a function-blocking anti-C5 mAb BB5.1. First
reported over 30 years ago, BB5.1 was generated by
immunization of C5-deficient mice and blocked haemoly-
sis in normal mouse serum.9 BB5.1 not only provided a
strong proof-of-concept for the therapeutic impact of
inhibition of C5a/MAC, but also focused attention on C5
as target. BB5.1 was tested in mouse models of arthritis,
renal injury, myasthenia gravis, multiple sclerosis, trans-
plantation, immune complex disease, ischaemia–reperfu-
sion injury, uveitis, colitis, meningitis, sepsis and
pemphigus; in this long list of diverse model diseases
BB5.1 was effective and safe.10–19
The success of BB5.1 provided the rationale for the
generation of human-specific blocking anti-C5 mAb.
Indeed, as early as 1996, a human C5 blocking mAb
5G1.1 was described that was modified, humanized and
finally marketed as eculizumab in 2002.20–23 Eculizumab
binds the C5a-chain MG7 domain at an epitope spanning
K879 to R885, remote from the a-chain C5 convertase
cleavage site (R751–L752), acting as a conformational
lock and preventing C5 from binding the convertase.4,23–
25 Recent reports highlight the complexity of the eculizu-
mab epitope on C5, with multiple residues outside the
K879–R885 epitope playing important roles; for example,
residues T916 and W917, which are unique to human
C5, are involved in eculizumab binding and probably
explain the lack of cross-reactivity of this mAb with C5
from other species, including non-human primates.26,27
The historical importance of BB5.1 as a catalyst for the
development of anti-complement drugs is clear and it
remains a useful and popular tool for proof-of-concept
studies in different models; however, its binding
characteristics and mechanism of inhibition remain
unknown. Here, we characterized the BB5.1 mAb, includ-
ing its binding to and inhibition of C5 from different
species, its binding affinities for mouse C5, its mechanism
of action and its C5-binding interface. We show that Fab
fragments of the mAb are efficient C5 inhibitors and pro-
vide complementarity-determining region (CDR)
sequence data that enabled in silico prediction of its bind-
ing site on C5 and will facilitate future modifications of
this unique mAb. We anticipate that a better understand-
ing of the mechanism of action of this venerable mAb
will further enhance its usefulness for the research com-
munity.
Materials and methods
All chemicals, except where otherwise stated, were
obtained from either Fisher Scientific UK (Loughborough,
UK) or Sigma Aldrich (Gillingham, UK) and were of ana-
lytical grade. All tissue culture reagents and plastics were
from Invitrogen Life Technologies (Paisley, UK). Sheep,
rabbit and guinea pig erythrocytes in Alsever’s solution
were from TCS Biosciences (Claydon, UK). Eculizumab
was donated by Professor David Kanavagh (Newcastle
University, UK), and the novel anti-C5 mAb crovalimab
(RO7112689) was donated by Roche Diagnostics (Basel,
Switzerland).
Human and animal (mouse, rat, rabbit and guinea pig)
sera were prepared in-house from freshly collected blood.
For all species except mouse, blood was clotted at room
temperature for 1 hr, and then placed on ice for 2 hr for
clot retraction before centrifugation and harvesting of
serum. For mouse, blood was placed on ice immediately
after harvest and clotted for 2 hr on ice before serum
harvest. Sera were stored in aliquots at 80° and not sub-
jected to freeze–thaw cycles.
Production and isotyping of BB5.1
The hybridoma cell line producing BB5.1 was re-cloned
and expanded; the antibody (mAb) was produced in large
quantities using Integra flasks [Integra Biosciences (Tathc-
ham, Berkshire, UK), Generon, CeLLine 1000 DC-90005)
in medium supplemented with ultralow IgG fetal bovine
serum (ThermoFisher, Loughborough, UK), and purified
Figure 1. Haemolytic assays to investigate BB5.1 inhibition of complement-mediated lysis across species. In classical pathway assays (CH50; a–f),
sera used were human (a), rabbit (b), guinea pig (c), rat (d) and mouse (e,f). BB5.1 only inhibited haemolysis in mouse serum, confirming that
it is specific for mouse C5. Commercial anti-C5 monoclonal antibody (mAb) crovalimab and eculizumab and in-house anti-C5 7D4 were used as
comparators. BB5.1-derived Fab fragment inhibited mouse serum-mediated haemolysis as effectively as the full-length BB5.1 (f). BB5.1 also effi-
ciently inhibited mouse serum mediated haemolysis in an alternative pathway assay (AH50; g). All tested mAbs except BB5.1 strongly inhibited
human C5, 7D4 strongly inhibited rat C5 and partially inhibited guinea pig. Crovalimab weakly inhibited mouse, guinea pig and rabbit comple-
ment. The 50% inhibitory doses (EC50) for each antibody and serum (except guinea pig as none reached 50% inhibition) were calculated (h). All
experiments were repeated three times with comparable results. The error bars are standard errors of triplicates.
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under sterile conditions on a 5-ml HiTrap Protein G
sepharose column (GE Healthcare, Amersham, UK;
#GE17-0405-01). Purity of the mAb was confirmed by
sodium dodecyl sulphate–polyacrylamide gel elec-
trophoresis (SDS–PAGE) and the isotype was tested using
IsoStrips (#11493027001; Roche).
Haemolytic assays
The inhibitory activity of BB5.1 in human and animal
sera was investigated using haemolysis assays. For the
classical pathway (CP; CH50) assay, sheep erythrocytes
(ShE) were sensitized by incubation using rabbit anti-ShE
antiserum (#ORLC25, Siemens Amboceptor; Cruinn
Diagnostics, Dublin, UK; ShEA), then suspended in
HEPES-buffered saline (HBS) containing Ca2+ and Mg2+
at 2% (vol:vol); for measurement of CP activity in male
mouse serum, ShEA were additionally incubated with
mouse anti-rabbit IgG (#3123; Invitrogen; 25 µg/ml) for
30 min at 37° before washing and re-suspending in
HBS.28 Serum dilutions for each species were selected in
preliminary experiments to give near complete haemolysis
in the CP assay in the absence of test mAb: normal
human serum, 25%; normal male mouse serum, 25%
(using the double-sensitized cells as described above);
normal rat serum, 25%; normal guinea pig serum, 25%;
normal rabbit serum, 25%. A serial dilution series of
BB5.1 mAb (667–0 nM for intact mAb; 2000–0 nM for
Fab) was prepared in HBS and aliquoted in triplicate into
a 96-well round-bottomed plate at 50 µl/well, then serum
at the appropriate dilution and 2% ShEA (50 µl/well of
each; double-sensitized for mouse as above) was added.
Plates were incubated at 37° for 30 min, centrifuged and
haemoglobin in the supernatant was measured by absor-
bance at 405 nm. For the alternative pathway (AP; AH50)
haemolysis assay, unsensitized rabbit erythrocytes (RbE)
were suspended in HBS containing 5 mM EGTA and
3 mM MgCl2 at 2% (vol:vol). Lytic serum dose was set
and test mAbs were titrated for inhibition essentially as
described for the CP assay. For each assay, percentage
lysis was calculated according to: % Lysis = Absorbance
(Abs) sample  Abs background)/(Abs max  Abs back-
ground) 9 100%. GRAPHPAD PRISM (v. 5.0) was used for
data analysis (GraphPad, San Diego, CA).
Characterization of BB5.1 by ELISA
Direct enzyme-linked immunosorbent assay (ELISA) was
used to test whether BB5.1, either intact mAb or Fab
fragments, bound mouse or human C5, as previously
described.29 Maxisorp (Nunc, Loughborough, UK) 96-
well plates were coated with mouse or human C5 (puri-
fied in-house; 05 µg/ml in bicarbonate buffer, pH 96) at
4° overnight; wells were blocked [1 hr at 37° with 2%
bovine serum albumin (BSA) in phosphate-buffered saline
(PBS)] and washed in PBS containing 005% Tween20
(PBS-T). Dilutions of purified BB5.1, intact mAb or Fab;
5–0 and 20–0 µg/ml, respectively (stock concentrations of
all proteins established using the BCA assay), in 02%
BSA-PBS, were added in triplicate to wells coated with
mouse or human C5 and incubated for 1 hr at 37°. Wells
were washed with PBS-T then incubated (1 hr, 37°) with
secondary antibody Peroxidase AffiniPure Donkey Anti-
Mouse IgG (H + L) (minimal cross-reactivity: bovine,
chicken, goat, guinea pig, Syrian hamster, horse, human,
rabbit, sheep serum proteins) or Peroxidase AffiniPure F
(ab’)2 Fragment Donkey Anti-Human IgG (H + L) (min-
imal cross-reactivity: bovine, chicken, goat, guinea pig,
Syrian hamster, horse, mouse, rabbit, rat, sheep serum
proteins) horseradish peroxidase (HRP) labelled; 715-035-
150; 709-036-149; Jackson ImmunoResearch, Ely, UK) for
1 hr at 37°. After washing, plates were developed using
O-phenylenediamine dihydrochloride (Sigma-Aldrich)
and absorbance (492 nm) was measured. GRAPHPAD PRISM
(v. 5.0) was used for data analysis.
Generation of BB5.1 Fab fragments
Fab fragments were generated from intact mAb (Pierce,
Amersham, UK; #44980) to test C5 binding capacity and
inhibitory activity after the enzymatic digestion. BB5.1 was
buffer exchanged using zebra spin desalting columns
(7KMWCO; Pierce; #89889) to freshly prepared digestion
buffer (1 mM EDTA, 50 mM sodium phosphate, 2 mM Cys-
teine-HCl-H2O, pH7). Immobilized ficin (1 ml of suspen-
sion; Pierce; #44881), recommended for IgG1 mAb, was
washed by centrifugation in digestion buffer, re-suspended
in 2 ml of buffer-exchanged mAb (10 mg), then incubated
for 2 hr at 37° followed by 24 hr incubation at room tem-
perature, with gentle mixing during the incubation. The
resin was washed three times by centrifugation with 5 ml
PBS, the wash fractions containing the digested antibody
combined and applied to a Protein A or G column (GE
Healthcare; # 17-0402-01, # 29-0485-81), to remove Fc-
containing proteins according to the manufacturer’s
instruction. The run-through containing Fab fragments
was collected, and bound Fc and residual intact mAb were
eluted using 01 M glycine pH 25. The Fab fragments were
analysed on SDS–PAGE under non-reducing and reducing
conditions, dialysed against HBS buffer and stored at 20°.
Characterization of BB5.1 by Western blot
Mouse and human C5 (in-house; 1 µg) were resolved on
SDS–polyacrylamide gels under reducing (5% b-mercap-
toethanol) and non-reducing conditions, then elec-
trophoretically transferred onto a 045-µm nitrocellulose
membrane (GE Healthcare). After transfer, non-specific
sites on the membrane were blocked with 5% BSA in
PBS-T. After washing in PBS-T, membranes were
ª 2020 The Authors. Immunology published by John Wiley & Sons Ltd, Immunology, 161, 103–113106
W. M. Zelek et al.
incubated for1 hr at room temperature with biotinylated
BB5.1 (1 µg/ml; Pierce, #21327) in 5% BSA PBS-T. After
washing, bound biotinylated test mAb was detected with
Streptavidin-HRP (R&D Systems, Abingdon, UK; #
890803) 1 : 5000 dilution in 5% BSA PBS-T, incubated
for 40 min at RT. After washing, the blot was developed
with enhanced chemiluminescence (GE Healthcare) and
visualized by autoradiography.
Testing whether BB5.1 inhibits generation of C5a from
mouse C5 by the CVF C3/C5 convertase
Mouse C5 was mixed with BB5.1 at 1 : 5 molar excess in
HBS, or with OmCI (tick saliva C5-blocker; Ornithodoros
moubata; coversin) at 1 : 10 molar ratio, then incubated
for 30 min at room temperature. Cobra venom factor
(CVF from Naja naja kaouthia) C3/C5 convertase
(CFVBb; Mr of complex ~ 205 000) was generated by
mixing CVF with human factor B (FB) and factor D
(FD) at a 1 : 1 : 01 molar ratio in HBS containing 5 mM
MgCl2 and incubated for 1 hr at 37°.
30 CVF and FB were
in-house purified as described previously;31 FD was pur-
chased from CompTech (Tyler, TX; A136). Preassembled
CVF convertases were added to the pre-incubated BB5.1–
C5 and OmCI–C5 complexes or C5 at 1 : 10 molar ratio
and incubated at 37°; aliquots were taken at 0, 1 and
12 hr. For Western blot, samples were diluted 1 in 3 in
HBS, separated and transferred as above, then probed
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Figure 2. Measuring binding of BB5.1 monoclonal antibody (mAb) to human and mouse C5. In direct ELISA, plates were coated with mouse
C5 (a) or human C5 (b); BB5.1 (full-length IgG and Fab) detected mouse C5 but not human C5 in the assay. Signals obtained for Fab fragments
and full mAb were comparable. All experiments were repeated three times with comparable results. The error bars are standard errors of tripli-
cates. (c) BB5.1 was immobilized directly onto a CM5 sensor chip by amine coupling at ~ 200 RU. Mouse C5 was flowed in HBS-EP at 52–4 nM
and interactions with the immobilized mAb were analysed. Sensorgrams were collected and KDs were calculated using the Langmuir 1 : 1 bind-
ing model. Representative sensorgrams are shown with fitted data in black (n = 3). As expected, BB5.1 bound strongly mouse C5; the association
constant (ka) was 156 9 105 min1, the dissociation constant (kd; koff) was 00013 s1, and the calculated KD was 810 9 109 M. (d) Purity of
the Fab was assessed by SDS–PAGE on 4–20% gel (Biorad, Watford, UK; #4561093) under non-reducing (NR) and reducing (R) conditions,
stained with Coomassie blue. As expected, the Fab runs at 50 000 NR and 25000 R. M, molecular weight marker (PageRuler #26620). The con-
taminant at ~ 30 000 in the protein G lanes represents protein G released from the solid phase during BB5.1 Fab purification; to avoid this issue,
protein A was selected for all bulk Fab preparations.
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with rabbit polyclonal goat anti-human C5 at 2 µg/ml
(CompTech; A220), detected using rabbit anti-goat-HRP
conjugate at 1 : 10 000 dilution (# 305-035-045; Jackson
ImmunoResearch). Positive controls included CVFBb
incubated with mouse C5 for 12 hr, intact mouse C5 (in
house), C5a (Comptech, A144) diluted in HBS.
Surface plasmon resonance measurement of BB5.1 bind-
ing affinity to mouse C5
Surface plasmon resonance (SPR) binding analyses were
carried out on a Biacore T200 instrument (GE Health-
care). BB5.1 was immobilized directly onto the CM5
sensor chip by amine coupling (#29-1496-03; GE Health-
care) at approximately 200 RU. Mouse C5 in HBS
(10 mM HEPES, pH 74, 150 mM NaCl, 005% surfactant
P20; HBS-EP) was flowed over the immobilized BB5.1 in
a concentration series from 52 to 4 nM and interactions
with the immobilized mAbs were analysed. For kinetic
analysis, the flow rate was maintained at 30 µl/min, and
data were collected at 25°. Data from a reference cell were
subtracted to control for bulk refractive index changes.
The Rmax was kept low and the flow rate was kept high
to eliminate mass transfer. All reagents used were of high
purity and polished by size exclusion chromatography
immediately before use to ensure removal of any
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Figure 3. Western blots to confirm BB5.1 C5 binding and test effect on C5 cleavage. (a) Mouse C5 (1 µg) was resolved on 4–20% SDS–PAGE
gel (Biorad, #4561093) under non-reducing (NR) and reducing (R; 5% b-mercaptoethanol) conditions, each in duplicate. The blot was probed
with biotinylated BB5.1 (1 µg/ml) and detected with streptavidin-horseradish peroxidase (R&D Systems, # 890803; 1 : 5000 dilution). Under NR
conditions BB5.1 bound intact C5 at 195 000 and a minor band at ~ 180 000, probably a C5 proteolytic fragment. Under NR conditions BB5.1
bound the mouse C5a-chain at 115 000 MW; there was no signal for the C5b-chain (80 000 MW). (b) Cleavage of mouse C5 by CVFBb. Mouse
C5, alone or mixed with BB5.1 or OmCI (1 : 5 and 1 : 10 molar excess, respectively) in HEPES-buffered saline (HBS), was incubated with
CVFBb at 10 : 1 (C5 : CVFBb) molar ratio for various periods up to 12 hr. The reaction was stopped by addition of SDS reduced buffer con-
taining 5% b-mercaptoethanol, samples (1 µg) resolved on 4–20% SDS–PAGE gels and Western blotted to detect intact or cleaved C5 and C5a
using polyclonal goat anti-C5 monoclonal antibody (mAb) (CompTech; A220). C5a (115 000), C5a’ (110 000), C5a (104 000). The inset table
shows densitometry analysis of the C5a band using IMAGEJ (University of Wisconsin-Maddison, Madison, WI, ), expressed as % relative to C5a
generation in the absence of inhibitor (100%); this confirms that BB5.1 efficiently inhibited cleavage of C5; no C5a was detected at any of the
incubation times. The C5 inhibitor OmCI did not inhibit C5 cleavage by CVFBb and resultant C5a generation. CVFBb was used at very low
amounts in the assays (~ 01 µg; 1 : 10 molar ratio with C5). Results are representative of three independent experiments.
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aggregates. Data were evaluated using BIACORE EVALUATION
software (GE Healthcare).
BB5.1 sequence determination and identification of CDR
Total mRNA was extracted from the BB5.1-producing
hybridoma and sent for antibody sequencing by whole
transcriptome shotgun sequencing (RNA-Seq; Absolute
Antibody, Oxford, UK). Contigs were assembled using a
proprietary approach and data were mined to identify all
viable antibody sequences. Variable heavy (VH) and vari-
able light (VL) domains were identified separately and
the relative abundance of each identified variable region
gene was reported in transcripts per million. The antici-
pated species and isotype of the BB5.1 antibody were
genetically confirmed. The CDRs for the primary VH and
VL sequences were automatically identified working to
the Kabat definition for CDRs.
Predicting the BB5.1-targeted epitope on C5 using com-
putational methods
The structure of BB5.1 was predicted using the ABODY-
BUILDER32 online pipeline (https://omictools.com/abodyb
uilder-tool Based on the mouse C5 sequence (https://
www.ncbi.nlm.nih.gov/protein/NP_034536.3) and human
C5 crystal structure (https://www.ncbi.nlm.nih.gov/prote
in/AAA51925.1); a coordinate structure of the mouse C5
was predicted using SWISS-Model.33 These two coordi-
nate files were inputted to the EpiPred server and used to
predict the most likely region of interaction between
BB5.1 and C5.34 Using the highest ranked epitope site as
the receptor site, these three-dimensional structures were
subjected to docking simulations using the molecular
operating environment (MOE; https://www.chemcomp.c
om/Products.html). The two structures were docked using
the protein–protein docking tool and used to identify the
most likely epitope on C5 and the key amino acids pre-
dicted to be important for binding. The structure with
the best score from the docking was selected and this
complex was subjected to 100 nanoseconds of molecular
dynamic simulation using the GROMACS suite.35 The
simulation involved placing the structure in a cubic box,
solvation using TIP3P-H2O and neutralization using
appropriate ions; long-range electrostatic interactions
were modelled using the particle mesh Ewald method and
a 14-nm cut-off was applied to Lennard–Jones interac-
tions. The Amber10 force field (http://ambermd.org/) was
selected for simulation. All of the simulations were car-
ried out in the isobaric-isothermal (NpT) ensemble at
310K with periodic boundary conditions. Each simulation
comprised: (i) energy minimization, using the steepest
descent method and a tolerance of 1000/KJ/nm; (ii)
warm-up stage of 25 000 steps at 0002 -ps steps with
atomic restraint applied to settle the model; (iii) a molec-
ular dynamic stage over a total of 100 nanoseconds. Fur-
ther to this, a second docking simulation was run using
the HADDOCK 2.4 server; all predicted epitope sites were
inputted into the server and these were ranked from most
to least likely conformer.
Results
Cross-species complement inhibition in haemolytic
assays
BB5.1 (subclass confirmed as IgG1, j-chain) was tested in
CP and AP haemolysis assays using human, rabbit, guinea
pig, rat and mouse sera; the mAb efficiently inhibited
haemolysis mediated by mouse serum but had no effect
in any of the other sera (Fig. 1a–e). Fab fragments gener-
ated from BB5.1 (Fig. 2d) also efficiently inhibited mouse
serum haemolysis (Fig. 1f). As we have reported before,29
eculizumab inhibited only human serum complement,
VH Sequence
VL Sequence
CDR-H1
CDR-L1 CDR-L2
CDR-L3
CDR-H2
CDR-H3
Figure 4. Complementarity determining region (CDR) sequencing of BB5.1. The figure shows the full variable heavy and variable light domain
sequences of BB5.1 monoclonal antibody (mAb); the CDRs (underlined and labelled in the variable domain sequences) were identified using the
Kabat CDR definitions in an automated program (https://absoluteantibody.com/).
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hereas the Roche anti-C5 mAb crovalimab additionally
inhibited mouse, guinea pig and rabbit sera; an in-house
anti-C5 mAb 7D436 blocked lysis mediated by human, rat
and guinea pig sera (Fig. 1a–d). BB5.1 also efficiently
inhibited AP haemolysis mediated by mouse serum
(Fig. 1g). The weak inhibition of CP and AP haemolysis
in mouse serum mediated by crovalimab contrasts with
BB5.1 strongly inhibiting both, suggesting that these
mAbs have different binding sites; the demonstration
(Fig. 3a) that BB5.1 binds the C5a chain whereas croval-
imab binds C5b confirms this.36 The calculated 50%
complement inhibitory doses (EC50) of all mAbs in the
different species sera are shown (Fig. 1h).
Binding of BB5.1 to mouse and human C5
The direct ELISA showed that both intact BB5.1 and Fab
fragments bound mouse C5 but not human C5 (Fig. 2a,
b). The strong binding of BB5.1 to mouse C5 was con-
firmed by SPR analysis on immobilized BB5.1 mAb
(200 RU) with mouse C5 flowed over; the calculated KD
was 81 9 109 M (Fig. 2c). The kinetics demonstrated a
very slow off-rate (kd; koff; 00013 s1) of mouse C5 from
mAb BB5.1, explaining why this mAb is such an efficient
inhibitor of complement in vivo. It was not possible to
test Fab fragments in SPR analyses because direct immo-
bilization of Fab on the chip markedly impacted C5 bind-
ing activity.
To test whether BB5.1 bound the a- or b-chain in
mouse C5, Western blotting was performed on purified
mouse C5; in reduced blots, BB5.1 bound the a-chain in
mouse C5 (Fig. 3a).
BB5.1 inhibits generation of C5a from mouse C5 by
the CVF C3/C5 convertase
To test whether BB5.1 inhibited convertase-mediated
cleavage to release C5a, mouse C5 was incubated with the
stable C3/C5 convertase CVFBb with or without an excess
of BB5.1 for up to 12 hr; C5a generation, detected by
Western blot, was used as an index of C5 cleavage. A
complete inhibition of CVFBb-mediated C5a generation
was observed when BB5.1 was included, even during a
12-hr incubation period; in contrast, inclusion of the tick
C5 inhibitor OmCI did not reduce C5a generation
(equivalent to the positive control; CVFBb+ mouse C5
alone), confirming that it did not block C5 cleavage by
the CVFBb convertase, as reported elsewhere.25 Densito-
metric analysis of the C5a band showed >99% inhibition
of C5a generation by BB5.1 compared with the positive
control (Fig. 3b).
CDR sequencing of BB5.1 and in silico determination
of binding epitopes on C5
The derived sequences of the BB5.1 CDRs are shown in
Fig. 4. The in silico modelling confirmed binding of
BB5.1 to mouse C5a chain and predicted the likely bind-
ing sites (Fig. 5a,b). The modelling predicted several
sequences in the MG7, MG8 and C345c domains as
potential epitopes (see insert table in Fig. 5c). Several of
these predicted epitopes, including a predicted epitope
site at 870–874 (Fig. 5c), were 100% conserved between
mouse C5 and C5 from other species and so are unlikely
to be key binding epitopes for this mouse C5-specific
mAb. As expected, mouse and rat C5 sequences were
highly homologous with the following residues in the
regions of interest being specific for mouse only; 826E,
853M, 858K, 881H, 885P, 926D, 1395H, 1396F, 1397R,
1398L, 1403F, 1515I, 1519R, 1537A. We therefore propose
that the most likely epitope site is that surrounding
1519R, where docking simulations from both MOE and
HADDOCK predicted that R1519 and L1520, located in
the MG8 domain at the interface with the C345c domain,
are key interacting residues, closely associated with CDRs
H1 and H3 in BB5.1 (Fig. 5a). These domains represent a
Figure 5. In silico modelling of the structure of the C5–BB5.1 complex. (a) Structure of the complementarity determining regions of BB5.1
docked to the predicted best epitope on mouse C5. The model shows that the BB5.1 binding site on C5 involves three domains, MG7, MG8 and
C345c domains (in light pink, pink and grey), adjacent in the tertiary structure; the zoomed-in view identifies the highest ranked interacting
amino acids identified in silico, R1519 and L1520 (arrowed; respectively yellow and red) located at the interface of the MG8 and C345c domains.
In the model, these residues contact BB5.1 CRDs H1 and H3. The interacting CDRs are highlighted in orange. (b) Cartoon diagram showing the
domain organization of C5 in the same orientation as the crystal structure in (a), mapping interaction sites of inhibitors; monoclonal antibody
(mAb) BB5.1, eculizumab, crovalimab, the tick inhibitors OmCI and RaCI. (c) Alignment of mouse and human, rat, rabbit and guinea pig C5
MG7 and MG8/C345c domain sequences. The arrow marks the interface between MG8 and C345c. Numbering for the mouse sequence is above.
An asterisk indicates positions that have a single, fully conserved residue. A: (A followed by a colon) indicates conservation between groups of
strongly similar properties – scoring >05 in the Gonnet PAM 250 matrix. A. (A followed by a period) indicates conservation between groups of
weakly similar properties– scoring ≤05 in the Gonnet PAM 250 matrix. In silico predicted BB5.1 epitopes are underlined in the mouse sequence;
the eculizumab epitope (K879–R885) is underlined in the human sequence. The mouse-specific residues are highlighted in boxes. The inset table
lists the in silico ranked BB5.1 epitopes in mouse C5 MG7, MG8 and C345c domains, with percentage conservation between human and mouse.
Alignments were performed using Uniprot CLUSTAL O(1.2.4) software (EMBL-EBI, Cambridge, UK; https://www.uniprot.org/align/) with the fol-
lowing sequences; mouse: P06684, human: P01031, rat: A0A1B0GWS5, rabbit: G1SPF9, guinea pig: H0UY41.
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critical region in C5 activation and MAC formation,
involved in C5 interaction with the C5 convertase and
also contributing to the interacting surface between C5b
and C7 during MAC assembly.37,38
Discussion
Although BB5.1 was the first complement activation
blocking mAb developed, and has been used in many
laboratories over many years,9 little was known about its
mechanism of C5 inhibition. Here, we have character-
ized BB5.1 and demonstrated that its function-blocking
activity is mouse specific, that it inhibits in both CP-
mediated and AP-mediated lysis assays, and that inhibi-
tory activity is retained in BB5.1-derived Fab fragments
(Fig. 1f–g). The strong binding of BB5.1 to mouse C5
was confirmed by ELISA, Western blotting and SPR
analysis, the latter demonstrating the strength and tenac-
ity of binding (KD = 810 9 109 M with slow off-rate;
koff 00013 s1 Figs 2a,c and 3a). BB5.1 showed no
interaction with human C5 in ELISA (Fig. 2b) or SPR
(negative data not shown), confirming the lack of any
binding activity.
The capacity of Fab fragments derived from BB5.1 to
efficiently inhibit C5 function establishes that intact anti-
body is not necessary for function and smaller, active
fragments may prove useful as tools for therapy studies.
Fab fragments are approximately 50 000 in mass, about a
third the size of intact antibody, and this may confer
advantages in accessing some tissue sites – for example,
the brain. Sequencing of the CDRs of BB5.1, reported
here, enables the generation of even smaller recombinant
fragments; recombinant single-chain variable fragments
have a mass of ~ 27 000 and are reported to cross the
blood–brain barrier.39,40 Generating single-chain variable
or other small recombinant fragments from the CDRs of
BB5.1 may allow proof-of-concept studies for C5 block-
ade in diseases of the central nervous system where the
blood–brain barrier is grossly intact, blocking ingress of
intact mAbs.
BB5.1 blocked the cleavage of mouse C5 by the stable
C3/C5 convertase CVFBb and consequent C5a generation;
the tick-derived C5 inhibitor OmCI, which binds epitopes
in the C5d, CUB and C345c domains, did not inhibit the
CVFBb convertase as previously reported (Fig. 3b).25
These data, together with published work,25,38 further
support the concept that C5 has multiple surface epitopes
that can be targeted by mAb or other agents to cause
inhibition of C5 cleavage and/or function, probably
through steric effects such as conformational locking.25
In silico modelling of the interaction of BB5.1 with
mouse C5 predicted specific interactions with residues in
the MG7, MG8 and C345c domains of the C5a-chain, co-
localized in a binding face on the molecule (Fig. 5). Ecu-
lizumab also binds the C5a-chain in a complex manner
with its key epitope located to K879 to R885 in MG7, but
with other contributing residues from outside MG7,
including the b-hairpin residues S913 to I922 that include
T916, W917, which are unique to human C5 and may
explain the human specificity of eculizumab.26,27 Individ-
uals expressing C5 with the R885H polymorphism, com-
mon in Japan with a prevalence of 35%, are resistant to
C5 blockade using this drug.41 The proximity of binding
sites for BB5.1 (predicted site) and eculizumab suggests
that they may have a similar mode of action; however,
further analyses, including mutations of predicted key
binding residues, are needed to confirm this possibil-
ity.4,25,38 Eculizumab is highly specific for human C5
whereas BB5.1 is specific for mouse C5 with no binding
or activity toward C5 from other species, including other
rodents (Fig. 1). To better understand these species
restrictions, the sequences of mouse, human, rat, rabbit
and guinea pig C5 across the key binding domains for
the two mAb were aligned (Fig. 5c). There was limited
conservation between human and mouse C5 in the key
eculizumab epitope, including a shape-shifting proline
substitution unique to mouse (KSSKCVR versus
RPSRCVF) and some of the predicted BB5.1-interacting
residues in mouse C5 were conserved in both human and
rat C5. Importantly, the key predicted interacting residues
in mouse C5, R1519 and L1520, were replaced by K and I
in the human sequence.
In summary, we show that BB5.1 and eculizumab bind
the C5a-chain at similar sites, the former predicted to
involve domains MG7, MG8 and C345c, the latter with a
primary epitope in MG7, and inhibit complement in the
same manner, blocking C5a generation as well as MAC
formation and acting as conformation locks, preventing
the structural ‘priming’ event that is necessary for the
cleavage. The work provides a mechanistic basis for the
activities of this landmark antibody, a much-used tool
that was a major impetus to the development of anti-
complement drugs for human disease.
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